Search the Newsreel

Eli Lilly (LLY) Stock Gets Fair Value Bump As Analysts Lift Targets On GLP1 Outlook

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Analysts have been lifting Eli Lilly price targets, with recent valuation work for the stock pointing to fair value of US$1,270.37 compared with …

Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts

As AI-related stocks weaken, investors are rotating into other sectors, such as energy and health care. Continue Reading

Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO

(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering. Most Read from Bloomberg Retina Chip Designed to Restore Sight to Go on Sale in Europe …

Eli Lilly Stock In A Buy Zone, Set To Ride The Peptide Wave

Eli Lilly stock hit an all-time high of 1,249.50 before pulling back into a buy zone above a pivot of 1,133.95. Continue Reading

Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing

This article first appeared on GuruFocus. Eli Lilly (LLY, Financials), a pharmaceutical firm that focuses on diabetes, obesity and other chronic diseases, said it aims to petition for regulatory approval of retatrutide in the first quarter of 2027 after the medicine succeeded in two …

Lilly Stock Is Rising on Plan to Seek Approval for Newest Weight-Loss Drug in 2027

Drugmaker Eli Lilly said Thursday that it is on track to seek federal approval for its next-generation obesity drug early next year. Lilly became the first drug company to reach a trillion dollar valuation last fall as sales of its weight loss drugs took …

Lilly to file for next-gen obesity drug approval in early 2027

Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and …

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type …

The Zacks Analyst Blog Highlights Eli Lilly, Costco Wholesale, Morgan Stanley and Kewaunee Scientific

For Immediate Release Chicago, IL – July 22, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …

Lilly confirms date and conference call for second-quarter 2026 financial results announcement

INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial …

Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown

Quarterly survey of 75 institutional investors active in healthcare delivers the first published, investor-assigned AI scores for 30 large-cap healthcare companies; Eli Lilly, UnitedHealth and Moderna lead Study highlights: In every healthcare subsector, 48% to 67% of investors say management overemphasizes AI relative to …

Top Research Reports for Eli Lilly, Costco & Morgan Stanley

Tuesday, July 21, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Costco Wholesale Corp. (COST) and Morgan Stanley (MS), as well …

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings? Eli Lilly has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 per share while the index has …

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads

(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly's advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates. Most Read from Bloomberg Yemen's Houthis …

Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, …

Claude AI Disagrees With President Trump on Eli Lilly (LLY)

President Donald Trump recently praised Eli Lily at a public event and called it "a great company" and highlighted its planned $3.5 billion investment for a manufacturing plant in Pennsylvania. However, Claude AI begs to differ from Trump. The AI agent recently sold its …

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Eli Lilly (LLY) ended the recent trading session at $1,146.90, demonstrating a -2.73% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow lost 0.59%, and the Nasdaq, a tech-heavy index, lost 0.05%. The …

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension …

Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal

Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5. Continue Reading

Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says

Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout

Eli Lilly LLY announced that it has entered into a definitive agreement to acquire New York-based clinical-stage biotech AtaiBeckley ATAI for an initial upfront payment of $2.8 billion. Shares of ATAI were up 33.4% yesterday following the announcement of the news. Lilly's interest in …

LLYC alcanza un beneficio neto de 9 millones de euros en 2024 y marca un nuevo récord